Your browser doesn't support javascript.
loading
Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies.
Nazarova, Lidia; Rafidi, Hanine; Mandikian, Danielle; Ferl, Gregory Z; Koerber, James T; Davies, Christopher W; Ulufatu, Sheila; Ho, Jason; Lau, Jeffrey; Yu, Shang-Fan; Ernst, James; Sadowsky, Jack D; Boswell, C Andrew.
Afiliação
  • Nazarova L; Preclinical and Translational Pharmacokinetics, Genentech Research and Early Development, South San Francisco, California.
  • Rafidi H; Preclinical and Translational Pharmacokinetics, Genentech Research and Early Development, South San Francisco, California.
  • Mandikian D; Preclinical and Translational Pharmacokinetics, Genentech Research and Early Development, South San Francisco, California.
  • Ferl GZ; Preclinical and Translational Pharmacokinetics, Genentech Research and Early Development, South San Francisco, California.
  • Koerber JT; Biomedical Imaging, Genentech Research and Early Development, South San Francisco, California.
  • Davies CW; Antibody Engineering, Genentech Research and Early Development, South San Francisco, California.
  • Ulufatu S; Antibody Engineering, Genentech Research and Early Development, South San Francisco, California.
  • Ho J; In Vivo Studies, Genentech Research and Early Development, South San Francisco, California.
  • Lau J; In Vivo Studies, Genentech Research and Early Development, South San Francisco, California.
  • Yu SF; Translational Oncology, Genentech Research and Early Development, South San Francisco, California.
  • Ernst J; Translational Oncology, Genentech Research and Early Development, South San Francisco, California.
  • Sadowsky JD; Protein Chemistry, Genentech Research and Early Development, South San Francisco, California.
  • Boswell CA; Protein Chemistry, Genentech Research and Early Development, South San Francisco, California.
Mol Cancer Ther ; 19(4): 1052-1058, 2020 04.
Article em En | MEDLINE | ID: mdl-32024685

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores Fc / Antígenos de Histocompatibilidade Classe I / Compostos Radiofarmacêuticos / Anticorpos Monoclonais Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores Fc / Antígenos de Histocompatibilidade Classe I / Compostos Radiofarmacêuticos / Anticorpos Monoclonais Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article